Revance Therapeutics Investor Presentation — June 2020

Document content

COMPANY PRESENTATION

JUNE 20202FORWARD -LOOKING STATEMENTS / SAFE HARBOR / MARKET DATA

This presentation contains forward -looking statements, including forward -statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements

relate to: financial metrics and outlook; the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational product

candidates, including anticipated near -term milestones; development of a biosimilar to BOTOX®; timing and outcome of regulatory determinations regarding potential approval of

DaxibotulinumtoxinA and expected PDUFA date and commercial potential of our drug candidates; anticipated strategic and financ ialbenefits of our distribution agreement with

Teoxane; commercial acceptance and potential of our drug product candidates and our technologies, including with respect to t he RHA line of dermal fillers; status of commercial

collaborations, including collaboration agreement with Mylan, demand for our product candidates and drivers of demand; market size, adoption rate and potential revenue; growth

opportunities and product pipeline; our business strategy, timeline and other goals and market for our anticipated products, plans and prospects, including our pre -

commercialization plans; our ability to leverage our investment in our development and manufacturing platform; and our commer cial and intellectual property strategy.

These statements also address expected timing, completion and effects of the proposed transaction, the related benefits of th e HintMD platform and related technologies to

Revance and the combined business, market acceptance and opportunity, and the updated 2020 financial outlook and cash runway. These forward -looking statements are subject

to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Revance’s expectations and beliefs regarding these matters may not materialize. Actual

outcomes and results may differ materially from those contemplated by these forward -looking statements as a result of uncertaint ies, risks and changes in circumstances, including

but not limited to risks and uncertainties related to: the ability of the parties to consummate the proposed transaction, sat isfaction of closing conditions precedent to the

consummation of the proposed transaction, potential delays in consummating the transaction and the ability of Revance to time ly and successfully achieve the anticipated benefits

of the transaction. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward -looking statements